Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population
Affiliations: Department of Human Genetics, McGill University, Montreal, QC H3G1A4, Canada, Research Institute of The McGill University Health Centre, Montreal, QC H3G1A4, Canada, Research Centre of The University of Montreal Hospital Centre/Montreal Cancer Institute, Montreal, QC H3G1A4, Canada
- Published online on: April 20, 2015 https://doi.org/10.3892/ol.2015.3123
- Pages: 2787-2790
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...
This article is mentioned in:
French Canadian families with breast cancer and breast-ovarian cancer syndrome harbor specific BRCA1, BRCA2 and PALB2 germline mutations, which have been attributed to common founders. Mutations in these genes confer an increased risk to breast and ovarian cancers, and have been identified to play a role in and directly interact with the common homologous recombination DNA repair pathways. Our previous study described the case of a female diagnosed with breast cancer at 45 years old, who harbored the PALB2:c.2323C>T [p.Q775X] and BRCA2:c.9004G>A [p.E3002K] germline mutations, which have been found to recur in the French Canadian cancer families. As the frequency of double heterozygous carriers of breast‑ovarian cancer susceptibility alleles is unknown, and due to the possibility that there may be implications for genetic counseling and management for these carriers, the present study investigated the co‑occurrence of BRCA1/BRCA2 and PALB2 mutations in the French Canadian cancer families. The PALB2:c.2323C>T [p.Q775X] mutation, which is the only PALB2 mutation to have been identified in French Canadian cancer families, was screened in 214 breast cancer cases and 22 breast‑ovarian cancer cases from 114 BRCA1/BRCA2 mutation‑positive French Canadian breast cancer (n=61) and breast‑ovarian cancer (n=53) families using a tailored polymerase chain reaction‑based TaqMan® SNP Genotyping Assay. No additional PALB2:c.2323C>T [p.Q775X] mutation carriers were identified among the BRCA1/BRCA2 mutation carriers. The results suggest that carriers of the PALB2:c.2323C>T [p.Q775X] mutation rarely co‑occur in French Canadian breast cancer and breast‑ovarian cancer families harboring BRCA1 or BRCA2 mutations.